Zhimeng Biopharma Snares ¥230M Series A Round

Shanghai Zhimeng Biopharma Inc. announced that it had closed 230 million Yuan in series A round, led by Trinity Innovation Fund, and co-invested by SDIC, Oceanpine Healthcare Fund, Photon Fund and a few other investors.

The funds will be mainly used for the phase Ib clinical study of the hepatitis B virus nucleocapsid inhibitor ZM-H1505R, which has a globally exclusive chemical structure, and the company's other pipeline clinical applications.

Shanghai Zhimeng Biopharma Inc. is a startup biotech founded in 2017 by seasoned pharmaceutical industry veterans. Located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, China, Zhimeng is developing medicines for the treatment of chronic hepatitis B (CHB) and severe neurological diseases with great unmet medical needs. 

Realizing the complexity of the pathogenesis of chronic hepatitis HBV infection, Zhimeng has adopted a comprehensive approach to tackle the diseases by directly hitting the hepatitis B virus (HBV) with multiple pronged attacks, as well as restoring the host immune systems. Our goal is to deliver innovative, most effective, safe and affordable therapies to bring a cure for patients suffering from CHB.  

Different from the reported Type I and Type II HBV core protein allosteric modulators (CpAMs), ZM-H1505R is a novel pyrazole molecule that has a new binding site in the HBV core protein. It inhibits HBV replication by hindering the packaging of pre-genomic RNA (pgRNA) into the viral capsid and by blocking the formation of HBV covalently closed circular DNA (cccDNA).

Founded in 2018, Trinity Innovation Fund (TIF) is dedicated to investing on biomedical innovations. Currently we are managing two funds with different focuses. Our limited partners (LPs) include renowned biopharmaceutical companies and investment institutions.